Citation Impact
Citing Papers
Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysis
2011
Interaction between Cigarette Smoking and Hepatitis B and C Virus Infection on the Risk of Liver Cancer: A Meta-analysis
2010
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
2007 StandoutScience
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection
2016
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNatureNobel
Long‐term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosis
2015
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
2012
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
2019 Standout
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
2016
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population
2012
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study
2006
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States
2002
Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis B
2006
Nasopharyngeal carcinoma
2005 Standout
Global Epidemiology of Hepatocellular Carcinoma
2015
Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance
2014
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
2012
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Reversion of disease manifestations after HCV eradication
2016
Hepatitis B Virus Infection — Natural History and Clinical Consequences
2004 Standout
Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B
2003
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders
2003
Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
2013
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
2013
Primary liver cancer: Worldwide incidence and trends
2004 Standout
Body Fatness and Cancer — Viewpoint of the IARC Working Group
2016 Standout
Infections and cancer: Established associations and new hypotheses
2008
Surveillance for Hepatocellular Carcinoma and Early Diagnosis
2007
Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B
2013
Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study
2014
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden
2009
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
2012
Obesity, inflammation, and liver cancer
2011
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
2008
Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy
2015
Ribavirin and Interferon Is Effective for Hepatitis C Virus Clearance in Hepatitis B and C Dually Infected Patients
2003
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis
2010
Interaction between cigarette, alcohol and betel nut use on esophageal cancer risk in Taiwan
2006
Burden of liver diseases in the world
2018 Standout
Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy
2003
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients
2016
Hepatitis B: Reflections on the current approach to antiviral therapy
2008
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up
2016
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B
2008
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
2008
Cost-effectiveness Analysis of a Two-stage Screening Intervention for Hepatocellular Carcinoma in Taiwan
2010
Hepatitis B Virus Infection
2008
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis
2009
Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B
2010
Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies
2012
Hepatitis C Infection
2017
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
2012
Head and neck cancer
2008 Standout
Focus on hepatocellular carcinoma
2004
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
2008
Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years
2007
Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion
2006
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States
2002
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis
2016
Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan
2003
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
2005
Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Endometrial Cancer
2020
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
2014
The global health burden of infection‐associated cancers in the year 2002
2006 Standout
The clinical significance of persistently normal ALT in chronic hepatitis B infection
2007
Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B
2011
Hepatocellular carcinoma
2012 Standout
Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan) σ
2010
Hepatitis B virus infection
2009 Standout
Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic
2009
Rescue therapy for lamivudine‐resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add‐on lamivudine combination therapy
2010
Hepatitis B cure: From discovery to regulatory approval
2017
The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
2016
The role of quantitative hepatitis B surface antigen revisited
2016
Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project)
2005
Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005
2006
Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
2015
Estimation of cancer cases and deaths attributable to infection in China
2011
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
2016
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma
2016
Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients
2016
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
2004
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
2013
A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation
2016
Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees
2014
Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population
2003
Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants
2012
From NAFLD in clinical practice to answers from guidelines
2013
Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy
2004
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
2016
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Management of Hepatocellular Carcinoma: An Update Δσ
2011 Standout
Management of Hepatocellular Carcinoma *
2005 Standout
Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily
2012
Global cancer statistics
2011 Standout
Molecular biology of hepatitis B virus infection
2015
Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors
2014
The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen
2015
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
2005
Liver cancer: Approaching a personalized care
2015
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma
2006
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
2004 Standout
Management of treatment failure in chronic hepatitis B
2012
Serum Immunoglobulin A Response to Human Papillomavirus Type 16 Virus–Like Particles in Human Immunodeficiency Virus (HIV)–Positive and High‐Risk HIV–Negative Women
2003
Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa
2009
Quantification of Plasma Epstein–Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma
2004
Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
2008
Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers
2006
Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase†
2007
Hepatitis B Virus and Cancer Prevention
2010
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
2007 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Role of antiviral treatment for HCC prevention
2014
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Hepatitis C virus-induced hepatocarcinogenesis
2009
Chronic hepatitis B
2007 Standout
Comparison of Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization
2013
Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis
2013
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
2006
Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B
2015
The natural history of chronic hepatitis B virus infection #
2009
Estimation of the Healthy Upper Limits for Serum Alanine Aminotransferase in Asian Populations With Normal Liver Histology
2009
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B
2008
Chronic hepatitis B: Update 2009 #
2009 Standout
Role of viral factors in the natural course and therapy of chronic hepatitis B
2007
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
2012 Standout
Diagnostic Accuracy of Point-of-Care Tests for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis
2015
Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
2017
Optimal management of hepatitis B virus infection – EASL Special Conference
2015
Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma
2010
Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B
2008
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B
2009
Management of HCC
2012
Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis
2013
Predictive Factors for Reactivation of Hepatitis B Following Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B
2007
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines
2013
What Is Killing People with Hepatitis C Virus Infection?
2011
Mechanisms of HBV-related hepatocarcinogenesis
2010
Efficacy of Tenofovir Disoproxil Fumarate At 240 Weeks in Patients With Chronic Hepatitis B With High Baseline Viral Load
2013
Animal models of nonalcoholic fatty liver disease
2010
Global control of hepatitis C: where challenge meets opportunity
2013
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
2007
Hepatitis B virus infection
2018
Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B
2013
Nationwide Hepatitis B Vaccination Program in Taiwan: Effectiveness in the 20 Years After It Was Launched
2006
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
2012
Cancer risks from betel quid chewing beyond oral cancer: a multiple-site carcinogen when acting with smoking
2010
Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
2014
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
2015
Response-Guided Peginterferon Therapy in Hepatitis B E Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
2013
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B
2012
Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
2017
Hepatitis B virus and hepatitis C virus dual infection
2014
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
2014
Diagnosis and management of chronic viral hepatitis: Antigens, antibodies and viral genomes
2008
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection
2014
NF-κB functions as a tumour promoter in inflammation-associated cancer
2004 StandoutNature
Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
2005
Spontaneous relapse of hepatitis in inactive HBsAg carriers
2007
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
2006
Habitual Betel Quid Chewing and Risk for Hepatocellular Carcinoma Complicating Cirrhosis
2004
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review
2012
HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics
2016
On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir
2013
Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients
2007
Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis
2012
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
2015
Hepatocellular Carcinoma
2011 Standout
Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants
2017
Treatment with lamivudine and entecavir in severe acute hepatitis B
2016
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
2014
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
2014
Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan
2004
Surveillance for hepatocellular carcinoma
2016
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
2013
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
2006
Head and Neck Cancer
2001 Standout
Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants
2008
Entecavir therapy for lamivudine‐refractory chronic hepatitis B
2008
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany
2015
The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection
2017
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations
2020
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
2015
Hepatocellular Carcinoma
2019 Standout
Epidemiology of Hepatocellular Carcinoma
2005
The Enigmatic Epidemiology of Nasopharyngeal Carcinoma
2006 Standout
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy
2015
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B
2013
Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
2010
AASLD guidelines for treatment of chronic hepatitis B
2015
Surveillance for Hepatocellular Carcinoma in Patients with NASH
2016
Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA Antibody
2004
Cancer statistics in China, 2015
2016 Standout
Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA
2016
Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population
2014
A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone
2005
Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
2015
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial
2015
Protective Interventions to Prevent Aflatoxin-Induced Carcinogenesis in Developing Countries
2007
Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection
2016
Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B
2016
Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus
2014 StandoutNobel
Factors associated with HBV Virological Breakthrough
2016
A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B
2005
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Cancer statistics, 2016
2016 Standout
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
2009
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
2010
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Human Fatty Liver Disease: Old Questions and New Insights
2011 StandoutScience
The evolving epidemiology of hepatocellular carcinoma: a global perspective
2015
Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta‐analysis
2016
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long‐term nucleos(t)ide analogue therapy
2014
Surveillance for hepatocellular carcinoma
2014
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
2007
The impact of hepatitis C burden: an evidence‐based approach
2014
Treatment With Ledipasvir–Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection
2016
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy
2006
Global cancer statistics, 2012
2015 Standout
Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections
2012
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
2015
Nonalcoholic Fatty Liver Disease
2015 Standout
The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.
2015
Prospective Evaluation of Hepatitis B 1762T/1764A Mutations on Hepatocellular Carcinoma Development in Shanghai, China
2009
Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
2013
Factors influencing liver disease progression in chronic hepatitis B
2006
Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography–defined subclinical cirrhosis
2015
Works of Hwai‐I Yang being referenced
Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection
2010
Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
2013
Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study
2017
Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma
2011
Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan
2008
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
2006
Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection
2007
Natural history of chronic hepatitis B REVEALed
2011
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
2011
Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study
2010
Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan
2012
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
2002
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B # †
2009
Serologic Markers of Epstein–Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men
2001
Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
2012
Prediction Models of Long-Term Cirrhosis and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: Risk Scores Integrating Host and Virus Profiles
2013
Synergism Between Obesity and Alcohol in Increasing the Risk of Hepatocellular Carcinoma: A Prospective Cohort Study
2013
Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study
2007
Seropositivity of hepatitis B e antigen and hepatocellular carcinoma
2004
Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk
2015
A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection
2012
Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
2008
Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
2013
Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men
2010
Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression
2014
Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death
2010
Predictability of Liver-Related Seromarkers for the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
2013
Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan
2003
Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma
2013
Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan
2006
1141 Complete genotypic and phenotypic analyses of HBV mutations identified in HBEAG-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV)
2003
27 Risk of hepatocellular carcinoma associated with genotypes and mutants of hepatitis B virus: A community-based prospective cohort study
2006
Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study
2010
Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C
2011
Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease
2010
Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV)
2015
Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
2016
[222] RISK OF LIVER CIRRHOSIS ASSOCIATED WITH GENOTYPE AND MUTANTS OF HEPATITIS B VIRUS
2007
Epidemiology and natural history of hepatitis C virus infection.
2014
Natural history of chronic hepatitis B : what exactly has REVEAL Revealed?
2012
Updated thresholds for serum alanine aminotransferase level in a large‐scale population study composed of 34 346 subjects
2012
141 SERIAL MONITORING OF VIRAL LOAD AND SERUM ALANINE AMINOTRANFERASE LEVEL AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC): R.E.V.E.A.L.-HBV STUDY UPDATE
2008